F-FDG PET/CT 对脐尿管腺癌分期和治疗计划的临床应用价值。
Clinical Utility of F-FDG PET/CT for Staging and Treatment Planning in Urachal Adenocarcinoma.
机构信息
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Radiology, Weill Cornell Medical College, New York, New York.
出版信息
J Nucl Med. 2021 May 10;62(5):643-647. doi: 10.2967/jnumed.120.251561. Epub 2020 Sep 18.
Our objective was to evaluate the impact of F-FDG PET CT on the management of urachal adenocarcinoma (UrC-ADC). A retrospective analysis of patients with UrC-ADC from 2001 to 2019 at Memorial Sloan Kettering was performed. Mayo stage before F-FDG PET/CT, rate of detection of the primary malignancy and metastases on F-FDG PET/CT, Mayo stage after F-FDG PET/CT, and change in patient management were determined. Of 21 patients with UrC-ADC before F-FDG PET/CT, Mayo staging was I/II in 8, III in 3, and IV in 10. F-FDG PET/CT detected previously unidentified metastases in 8 (38%) of 21 patients, resulting in upstaging of disease in 3 (14%) patients and a change in treatment in 4 (19%) patients. F-FDG PET/CT has clinical utility in patients with UrC-ADC by identifying metastatic disease not appreciated on anatomic imaging, leading to changes in staging and patient management.
我们的目的是评估 F-FDG PET CT 对脐尿管腺癌 (UrC-ADC) 治疗管理的影响。回顾性分析了 2001 年至 2019 年 Memorial Sloan Kettering 接受治疗的 UrC-ADC 患者。确定了 F-FDG PET/CT 前的 Mayo 分期、F-FDG PET/CT 上原发性恶性肿瘤和转移灶的检出率、F-FDG PET/CT 后的 Mayo 分期以及患者管理的变化。在 F-FDG PET/CT 前的 21 例 UrC-ADC 患者中，8 例（38%）为 Mayo I/II 期，3 例为 III 期，10 例为 IV 期。F-FDG PET/CT 在 21 例患者中发现了先前未识别的转移灶，其中 3 例（14%）患者疾病分期上调，4 例（19%）患者治疗方式改变。F-FDG PET/CT 通过识别解剖影像学未发现的转移性疾病，对 UrC-ADC 患者具有临床应用价值，可改变分期和患者管理。
Zotero 插件